JP6066499B2 - インスリンポンプ - Google Patents
インスリンポンプ Download PDFInfo
- Publication number
- JP6066499B2 JP6066499B2 JP2014525413A JP2014525413A JP6066499B2 JP 6066499 B2 JP6066499 B2 JP 6066499B2 JP 2014525413 A JP2014525413 A JP 2014525413A JP 2014525413 A JP2014525413 A JP 2014525413A JP 6066499 B2 JP6066499 B2 JP 6066499B2
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- patient
- value
- blood glucose
- gain factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 786
- 102000004877 Insulin Human genes 0.000 title claims description 392
- 108090001061 Insulin Proteins 0.000 title claims description 392
- 229940125396 insulin Drugs 0.000 title claims description 392
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 221
- 239000008103 glucose Substances 0.000 claims description 221
- 239000008280 blood Substances 0.000 claims description 112
- 210000004369 blood Anatomy 0.000 claims description 112
- 235000012054 meals Nutrition 0.000 claims description 69
- 230000003914 insulin secretion Effects 0.000 claims description 62
- 230000007812 deficiency Effects 0.000 claims description 48
- 238000012545 processing Methods 0.000 claims description 48
- 238000005094 computer simulation Methods 0.000 claims description 35
- 238000005259 measurement Methods 0.000 claims description 27
- 238000004364 calculation method Methods 0.000 claims description 23
- 150000001720 carbohydrates Chemical class 0.000 claims description 23
- 235000014633 carbohydrates Nutrition 0.000 claims description 23
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 21
- 238000007920 subcutaneous administration Methods 0.000 claims description 18
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 230000037406 food intake Effects 0.000 claims description 8
- 210000000496 pancreas Anatomy 0.000 claims description 8
- 239000004065 semiconductor Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- 150000002303 glucose derivatives Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
- 230000036961 partial effect Effects 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 208000013016 Hypoglycemia Diseases 0.000 description 14
- 230000002218 hypoglycaemic effect Effects 0.000 description 14
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 238000004422 calculation algorithm Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 235000011888 snacks Nutrition 0.000 description 8
- 230000000291 postprandial effect Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 238000010254 subcutaneous injection Methods 0.000 description 7
- 239000007929 subcutaneous injection Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 108010065691 Biphasic Insulins Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000189 biphasic insulin Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000028023 exocytosis Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000013433 optimization analysis Methods 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000001904 Arabinogalactan Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- 235000021074 carbohydrate intake Nutrition 0.000 description 2
- 238000011217 control strategy Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 239000010438 granite Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000006362 insulin response pathway Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000006406 biphasic response Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001201 calcium disodium ethylene diamine tetra-acetate Substances 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011473 radical retropubic prostatectomy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029964 regulation of glucose metabolic process Effects 0.000 description 1
- 230000010656 regulation of insulin secretion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14208—Pressure infusion, e.g. using pumps with a programmable infusion control system, characterised by the infusion program
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
- A61M2005/1726—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure the body parameters being measured at, or proximate to, the infusion site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1113933.4 | 2011-08-12 | ||
| GB1113933.4A GB2493712B (en) | 2011-08-12 | 2011-08-12 | Insulin pump |
| PCT/EP2012/065725 WO2013024044A2 (en) | 2011-08-12 | 2012-08-10 | Insulin pump |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524294A JP2014524294A (ja) | 2014-09-22 |
| JP2014524294A5 JP2014524294A5 (enExample) | 2015-10-08 |
| JP6066499B2 true JP6066499B2 (ja) | 2017-01-25 |
Family
ID=44764429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014525413A Expired - Fee Related JP6066499B2 (ja) | 2011-08-12 | 2012-08-10 | インスリンポンプ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9283323B2 (enExample) |
| EP (1) | EP2742449A2 (enExample) |
| JP (1) | JP6066499B2 (enExample) |
| CN (1) | CN104054081A (enExample) |
| GB (1) | GB2493712B (enExample) |
| WO (1) | WO2013024044A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8417311B2 (en) * | 2008-09-12 | 2013-04-09 | Optiscan Biomedical Corporation | Fluid component analysis system and method for glucose monitoring and control |
| ES2755497T3 (es) | 2010-10-31 | 2020-04-22 | Univ Boston | Sistema de control de glucosa en sangre |
| US11798685B2 (en) | 2012-05-15 | 2023-10-24 | James M. Minor | Diagnostic methods and devices for controlling acute glycemia |
| WO2013173499A2 (en) | 2012-05-15 | 2013-11-21 | Minor James M | Diagnostic methods and devices for monitoring chronic glycemia |
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| ES2895520T3 (es) * | 2013-10-21 | 2022-02-21 | Hoffmann La Roche | Unidad de control para unidades de bomba de infusión, incluyendo una unidad de intervención controlada |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
| CA2938078C (en) | 2014-01-31 | 2019-06-11 | Trustees Of Boston University | Offline glucose control based on preceding periods |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| JP6989262B2 (ja) | 2014-10-27 | 2022-01-05 | アセコー インコーポレイテッド | 皮下外来患者管理 |
| CN105688308A (zh) * | 2014-11-13 | 2016-06-22 | 上海泽生科技开发有限公司 | 注射泵控制方法、控制单元及注射泵 |
| JP2018525093A (ja) | 2015-08-07 | 2018-09-06 | トラスティーズ オブ ボストン ユニバーシティ | グルコース目標の自動適合を備えたグルコース制御システム |
| US10548528B2 (en) * | 2015-08-07 | 2020-02-04 | Ryan James Appleby | Smartphone device for body analysis |
| CA2993275C (en) | 2015-08-20 | 2022-06-21 | Aseko, Inc. | Diabetes management therapy advisor |
| CN105457123A (zh) * | 2015-11-26 | 2016-04-06 | 北京大学第一医院 | 一种大剂量甲氨蝶呤用药控制系统 |
| US10332632B2 (en) * | 2016-06-01 | 2019-06-25 | Roche Diabetes Care, Inc. | Control-to-range failsafes |
| CN110352460A (zh) * | 2016-10-13 | 2019-10-18 | 法国国家科学研究中心 | 人工胰腺 |
| EP3318294A1 (en) | 2016-11-08 | 2018-05-09 | Defymed | Kit for in situ delivery of a compound of interest |
| US11311668B2 (en) * | 2016-12-15 | 2022-04-26 | Verily Life Sciences Llc | Auto-calibration of physiological response estimates for closed-loop insulin delivery using patient-selected standardized meals |
| CN108261591B (zh) * | 2016-12-30 | 2021-10-08 | 上海移宇科技股份有限公司 | 一种人工胰腺的闭环控制算法 |
| WO2018147483A1 (ko) * | 2017-02-09 | 2018-08-16 | 최규동 | 연속 혈당 감지를 이용한 인슐린 투여 시스템 |
| US11147920B2 (en) * | 2017-04-18 | 2021-10-19 | Lifescan Ip Holdings, Llc | Diabetes management system with automatic basal and manual bolus insulin control |
| CA3059985C (en) | 2017-05-05 | 2023-08-08 | Eli Lilly And Company | Closed loop control of physiological glucose |
| EP3438858A1 (en) | 2017-08-02 | 2019-02-06 | Diabeloop | Closed-loop blood glucose control systems and methods |
| CA3085930A1 (en) | 2017-12-21 | 2019-06-27 | Eli Lilly And Company | Closed loop control of physiological glucose |
| US11915151B2 (en) * | 2018-08-27 | 2024-02-27 | Zoe Limited | Accuracy of test data outside the clinic |
| CN118750687A (zh) * | 2018-05-04 | 2024-10-11 | 英赛罗公司 | 基于控制算法的药物输送系统的安全约束 |
| JP2021528758A (ja) | 2018-06-22 | 2021-10-21 | イーライ リリー アンド カンパニー | インスリンとプラムリンタイドの送達システム、方法、およびデバイス |
| WO2020142655A1 (en) * | 2019-01-04 | 2020-07-09 | Abbott Diabetes Care Inc. | Systems, devices, and methods for improved meal and therapy interfaces in analyte monitoring systems |
| AU2020298305B2 (en) | 2019-06-19 | 2025-11-13 | Dexcom, Inc. | Dynamic equivalent on board estimator |
| CA3146872A1 (en) | 2019-07-16 | 2021-01-21 | Beta Bionics, Inc. | Blood glucose control system |
| DE112020003392T5 (de) | 2019-07-16 | 2022-05-19 | Beta Bionics, Inc. | Blutzuckerkontrollsystem |
| US11957876B2 (en) | 2019-07-16 | 2024-04-16 | Beta Bionics, Inc. | Glucose control system with automated backup therapy protocol generation |
| US11213623B2 (en) * | 2019-09-20 | 2022-01-04 | Medtronic Minimed, Inc. | Infusion systems and related personalized bolusing methods |
| CN115361981A (zh) * | 2020-01-30 | 2022-11-18 | 塞卡科实验室有限公司 | 冗余交错式葡萄糖传感器疾病管理系统 |
| EP3892259A1 (en) | 2020-04-09 | 2021-10-13 | Defymed | Membranes for medical devices |
| WO2021204935A1 (en) | 2020-04-09 | 2021-10-14 | Defymed | Membranes for medical devices |
| CN111632228B (zh) * | 2020-05-19 | 2021-05-25 | 中国科学院深圳先进技术研究院 | 一种基于可穿戴监测方法的闭环人工胰腺系统 |
| KR20220020108A (ko) * | 2020-08-11 | 2022-02-18 | 삼성전자주식회사 | 약물 전달 장치 및 약물 전달 장치의 동작 방법 |
| KR102521085B1 (ko) * | 2020-10-30 | 2023-04-12 | 이오플로우(주) | 인슐린 패치를 포함하는 인공췌장 제어 방법 및 그 장치 |
| US12465686B2 (en) | 2021-03-25 | 2025-11-11 | Beta Bionics, Inc. | Emergency medicament dose control |
| WO2023014660A1 (en) * | 2021-08-02 | 2023-02-09 | Tandem Diabetes Care, Inc. | Systems and methods for processing continuous glucose monitor values in automated insulin delivery |
| US20230040677A1 (en) * | 2021-08-03 | 2023-02-09 | Tandem Diabetes Care, Inc. | Systems and methods for automated insulin delivery response to meal announcements |
| WO2023070250A1 (en) * | 2021-10-25 | 2023-05-04 | Medtrum Technologies Inc. | Closed-loop artificial pancreas insulin infusion personalized control system |
| US20240424207A1 (en) * | 2021-10-25 | 2024-12-26 | Medtrum Technologies Inc. | Closed-loop artificial pancreas insulin infusion control system |
| USD1033628S1 (en) | 2022-08-12 | 2024-07-02 | Luminoah, Inc. | Fluid delivery module |
| USD1029235S1 (en) | 2022-08-12 | 2024-05-28 | Luminoah, Inc. | Fluid delivery system |
| USD1029236S1 (en) | 2022-08-12 | 2024-05-28 | Luminoah, Inc. | Fluid pouch assembly |
| AU2023324031A1 (en) | 2022-08-12 | 2025-02-20 | Luminoah, Inc. | Wearable fluid delivery system |
| WO2025188770A1 (en) * | 2024-03-04 | 2025-09-12 | University Of Virginia Patent Foundation | System and method for automated insulin delivery using artificial neural network |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7806886B2 (en) * | 1999-06-03 | 2010-10-05 | Medtronic Minimed, Inc. | Apparatus and method for controlling insulin infusion with state variable feedback |
| US20070173461A1 (en) | 2004-02-03 | 2007-07-26 | Nippon Shinyaku Co., Ltd. | Glycoside prodrug of 5- aminosalicylic acid |
| US9056165B2 (en) * | 2006-09-06 | 2015-06-16 | Medtronic Minimed, Inc. | Intelligent therapy recommendation algorithm and method of using the same |
| US20080146994A1 (en) * | 2006-10-10 | 2008-06-19 | Allen Gerber | Retrofittable aspiration prevention mechanism for patients |
| US20080172028A1 (en) * | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having selectable insulin absorption models |
| US10154804B2 (en) * | 2007-01-31 | 2018-12-18 | Medtronic Minimed, Inc. | Model predictive method and system for controlling and supervising insulin infusion |
| US20080206799A1 (en) * | 2007-02-27 | 2008-08-28 | Michael Blomquist | Carbohydrate ratio testing using frequent blood glucose input |
| EP2139540A1 (en) * | 2007-03-19 | 2010-01-06 | Medingo Ltd. | User interface for selecting bolus doses in a drug delivery device |
| US8827979B2 (en) * | 2007-03-19 | 2014-09-09 | Insuline Medical Ltd. | Drug delivery device |
| CN101801262A (zh) * | 2007-07-09 | 2010-08-11 | 弗吉尼亚大学专利基金会 | 糖尿病胰岛素敏感度、碳水化合物比、校正因子数据自我监测产品 |
| WO2010135670A2 (en) * | 2009-05-22 | 2010-11-25 | Abbott Diabetes Care Inc. | Safety layer for integrated insulin delivery system |
| US9687194B2 (en) * | 2009-06-17 | 2017-06-27 | Medtronic Minimed, Inc. | Closed-loop glucose and/or insulin control system |
-
2011
- 2011-08-12 GB GB1113933.4A patent/GB2493712B/en not_active Expired - Fee Related
-
2012
- 2012-08-09 US US13/570,525 patent/US9283323B2/en not_active Expired - Fee Related
- 2012-08-10 EP EP12748191.9A patent/EP2742449A2/en not_active Withdrawn
- 2012-08-10 WO PCT/EP2012/065725 patent/WO2013024044A2/en not_active Ceased
- 2012-08-10 CN CN201280050194.5A patent/CN104054081A/zh active Pending
- 2012-08-10 JP JP2014525413A patent/JP6066499B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014524294A (ja) | 2014-09-22 |
| GB2493712A (en) | 2013-02-20 |
| EP2742449A2 (en) | 2014-06-18 |
| GB201113933D0 (en) | 2011-09-28 |
| GB2493712B (en) | 2014-07-02 |
| CN104054081A (zh) | 2014-09-17 |
| US20130041343A1 (en) | 2013-02-14 |
| US9283323B2 (en) | 2016-03-15 |
| WO2013024044A2 (en) | 2013-02-21 |
| WO2013024044A3 (en) | 2013-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9283323B2 (en) | Insulin pump | |
| US20210361867A1 (en) | Integrated closed-loop medication delivery with error model and safety check | |
| US20250160696A1 (en) | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery | |
| Haidar | The artificial pancreas: How closed-loop control is revolutionizing diabetes | |
| US12623019B2 (en) | System, method, and computer readable medium for dynamic insulin sensitivity in diabetic pump users | |
| Marchetti et al. | A feedforward–feedback glucose control strategy for type 1 diabetes mellitus | |
| CN102596307B (zh) | 利用名义开环特性在糖尿病中进行胰岛素输送调节(aid)的系统、方法和计算机程序产品 | |
| EP2521483B1 (en) | System to deliver insulin to a subject | |
| EP4183326B1 (en) | Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes | |
| RU2641976C2 (ru) | Способ и система обработки ручного болюсного введения или введения в соответствии с приемом пищи в контроллерах с обратной связью | |
| JP2003079723A (ja) | 糖尿病管理装置 | |
| KR20120047841A (ko) | 당뇨병 관련 치료의 자동 감시를 위한 방법 및 시스템 | |
| Sasi et al. | A fuzzy controller for blood glucose-insulin system | |
| Allam et al. | Evaluation of using a recurrent neural network (RNN) and a fuzzy logic controller (FLC) in closed loop system to regulate blood glucose for type-1 diabetic patients | |
| Yasini et al. | Agent-based simulation for blood glucose control in diabetic patients | |
| Deichmann et al. | Model predictive control to account for prolonged changes in insulin requirements following exercise in type 1 diabetes | |
| Boiroux et al. | Overnight control of blood glucose in people with type 1 diabetes | |
| Al Ali et al. | A Comprehensive Review of Mathematical and Data-Driven Models in Glucose Homeostasis and Diabetes Pathways | |
| EP4591901A1 (en) | Adaptive closed-loop control method based on linear model | |
| Hernández et al. | High-order sliding-mode control for blood glucose regulation in the presence of uncertain dynamics | |
| Alsseid et al. | Comparative Analysis of PID Control Structures for Glucose Regulation in Type 1 Diabetes: A Simulation-Based Study Using the Bergman’s Model | |
| Grosman et al. | Model-based sensor-augmented pump therapy | |
| Hamata et al. | Exploring Equilibrium Points in a Long-term Glucose-insulin Model for Type I Diabetes: MPC Application in Automated Insulin Delivery Systems Using Functional Insulin Therapy Tools | |
| Wilinska et al. | Overnight closed-loop insulin delivery in patients with type 1 diabetes | |
| Hacısalihzade | Diabetes and Control of Blood Glucose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150807 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150807 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20151016 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20151104 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151207 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160302 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160406 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160727 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161026 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161121 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161219 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6066499 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |